MaxCyte to Report First Quarter 2022 Financial Results on May 9, 2022
20 avr. 2022 16h05 HE
|
MaxCyte, Inc
GAITHERSBURG, Md., April 20, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to...
MaxCyte Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
15 avr. 2022 09h00 HE
|
MaxCyte, Inc
GAITHERSBURG, Md., April 15, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform...
MaxCyte Announces Departure of CFO and Appointment of Ron Holtz as Interim CFO, Announces Preliminary First Quarter 2022 Revenue
12 avr. 2022 16h05 HE
|
MaxCyte, Inc
GAITHERSBURG, Md., April 12, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to...
MaxCyte Reports Fourth Quarter and Full Year Financial Results
22 mars 2022 16h05 HE
|
MaxCyte, Inc
GAITHERSBURG, Md., March 22, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT) is a leading commercial cell-engineering company focused on providing enabling platform technologies to...
MaxCyte, Inc. Names Cenk Sumen Chief Scientific Officer
09 mars 2022 16h15 HE
|
MaxCyte, Inc
GAITHERSBURG, Md., March 09, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform...
MaxCyte to Report Fourth Quarter and Full Year 2021 Financial Results on March 22, 2022
24 févr. 2022 08h00 HE
|
MaxCyte, Inc
GAITHERSBURG, M.D., Feb. 24, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform...
MaxCyte to Participate in Upcoming Investor Conferences
14 févr. 2022 08h00 HE
|
MaxCyte, Inc
GAITHERSBURG, Md., Feb. 14, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies...
MaxCyte Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11 févr. 2022 17h00 HE
|
MaxCyte, Inc
GAITHERSBURG, Md., Feb. 11, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies...
MaxCyte Signs Strategic Platform License with Intima Bioscience to Advance Tumor Infiltrating Lymphocytes Programs
01 févr. 2022 02h00 HE
|
MaxCyte, Inc
NEW YORK and GAITHERSBURG, Md., Jan. 31, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT, MXCN), a leading provider of enabling platform technologies for ex-vivo cell engineering,...
MaxCyte Announces Strong Preliminary Unaudited Fourth Quarter and Full Year 2021 Revenue Results
24 janv. 2022 02h30 HE
|
MaxCyte, Inc
Fourth quarter 2021 revenue expected to be greater than $10 million Full year 2021 revenue expected to be greater than $33.7 millionInstalled base of greater than 500 instruments 15 SPLs, covering...